|Articles|May 23, 2018
The Fundamental Disconnect Between Pharma and Technology
Author(s)Michelle Maskaly
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system.
Advertisement
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system, Abilify Mycite.
His interview was recorded during the May 2018 Financial Times Live ‘s US Healthcare & Life Sciences Summit in New York City.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
2
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape
5